0001735276-18-000074.txt : 20180928
0001735276-18-000074.hdr.sgml : 20180928
20180928165724
ACCESSION NUMBER: 0001735276-18-000074
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180927
FILED AS OF DATE: 20180928
DATE AS OF CHANGE: 20180928
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vaishnaw Akshay
CENTRAL INDEX KEY: 0001458494
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36407
FILM NUMBER: 181094783
MAIL ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001178670
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770602661
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 551-8200
MAIL ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020724
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2018-09-27
0
0001178670
ALNYLAM PHARMACEUTICALS, INC.
ALNY
0001458494
Vaishnaw Akshay
300 THIRD STREET
CAMBRIDGE
MA
02142
0
1
0
0
President, R&D
Performance Stock Option 2015 (right to buy)
88.95
2018-09-27
4
A
0
7500
0.0
A
2018-09-27
2025-12-18
Common Stock
7500
22500
D
Performance Stock Option 2016 (right to buy)
42.22
2018-09-27
4
A
0
6250
0.0
A
2018-09-27
2026-12-20
Common Stock
6250
12500
D
On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares
subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares.
On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares
subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares.
By: /s/ Michael P. Mason, Attorney-in-Fact For: Akshay K. Vaishnaw
2018-09-28